

September 7, 2021



# Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

AUSTIN, Texas--(BUSINESS WIRE)-- **Anebulo Pharmaceuticals, Inc.** (Nasdaq: ANEB) ("Anebulo" or the "Company"), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced that management will be participating in the H.C. Wainwright 23<sup>rd</sup> Annual Global investment Conference being held virtually on September 13-15, 2021. Management will deliver a company presentation and will be available for one-on-one meetings with investors. The recorded presentation will be available on demand beginning Monday, September 13<sup>th</sup> on the [Investors](#) section of Anebulo's website.

## About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism. For further information about Anebulo, please visit [www.anebulo.com](http://www.anebulo.com).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210907005053/en/>

## Anebulo Pharmaceuticals, Inc.

Rex Merchant  
Chief Financial Officer  
(512) 598-0931  
[IR@anebulo.com](mailto:IR@anebulo.com)

## LHA Investor Relations

Yvonne Briggs  
(310) 691-7100  
[ybriggs@lhai.com](mailto:ybriggs@lhai.com)

Source: Anebulo Pharmaceuticals, Inc.